Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
North Eastern Germany Society of Gynaecologic Oncology |
---|---|
Information provided by: | North Eastern Germany Society of Gynaecologic Oncology |
ClinicalTrials.gov Identifier: | NCT00170664 |
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer. Based on a phase I study now a multi-center phase II-trial was conducted.
Condition | Intervention | Phase |
---|---|---|
Ovarian Cancer |
Drug: Paclitaxel Drug: Carboplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Randomized, Open Label, Active Control, Single Group Assignment |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Female |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Charité Campus Virchow-Klinikum | |
Berlin, Germany, 13533 |
Principal Investigator: | Werner Lichtenegger | Charité Campus Virchow Klinikum |
Study ID Numbers: | 020114 |
Study First Received: | September 12, 2005 |
Last Updated: | November 8, 2005 |
ClinicalTrials.gov Identifier: | NCT00170664 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
- Ovarian neoplasms – paclitaxel, carboplatin – clinical trials, phase II – first-line chemotherapy - weekly therapy schedule |
Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases |
Carboplatin Ovarian epithelial cancer Genital Diseases, Female Paclitaxel Endocrinopathy Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Mitosis Modulators |
Tubulin Modulators Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions Adnexal Diseases |